Torrent Pharma.
Torrent Pharma. Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
India base business is expected to continue outperforming market growth with a focus on improving market share in key therapies and expanding the Curatio portfolio. JB Pharma margins improved to 35.3% in Q1 FY27, driven largely by cost synergies, with further incremental margin improvement expected quarterly though some reinvestment is planned.
From Torrent Pharma.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- India base business is expected to continue outperforming market growth with a focus on improving market share in key therapies and expanding the Curatio portfolio.
- Organic India growth excluding semaglutide showed a 15-16% trajectory; top 10 base brands are growing over 20%.
- JB Pharma business targets double-digit growth on a consolidated basis after integration completes in 6-9 months.
- New product launches and operating leverage in US business expected to stabilize and improve top-line and profitability.
- Brazil market expected to return to normalized mid-teens constant currency growth following temporary channel inventory correction.
- Germany market faces challenges but efforts on supply stabilization and tender wins ongoing with potential gradual recovery.
- Cost synergies from JB merger driving margin expansion; revenue synergies could be clearer post-integration over next 12-18 months.
2 more points from Torrent Pharma.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Torrent Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Torrent Pharma is cautiously evaluating capital allocation post-JB Pharma acquisition, which is only six months old.
- They prefer waiting for 12-18 months to assess integration success before pursuing new opportunities.
- The company aims not to exceed a net debt-to-EBITDA ratio of 3x to 3.5x in future investments.
- Preference is to prioritize Indian opportunities if similar in size to international ones.
2 more points from Torrent Pharma.'s call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Torrent Pharma. — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.2K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals Ltd's management said in earlier quarters
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Arthneeti Pro · Annual
Torrent Pharma. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Torrent Pharma. Q1 FY27 results?
India base business is expected to continue outperforming market growth with a focus on improving market share in key therapies and expanding the Curatio portfolio. JB Pharma margins improved to 35.3% in Q1 FY27, driven largely by cost synergies, with further incremental margin improvement expected quarterly though some reinvestment is planned.
What is Torrent Pharma. share price analysis?
Torrent Pharma. currently shows a below-average growth signal. The stock trades at a P/E of 83.5 with a market cap of ₹186,247 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharma. planning capital expenditure?
Torrent Pharma is cautiously evaluating capital allocation post-JB Pharma acquisition, which is only six months old.
Keep Torrent Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.